Werewolf Therapeutics, Inc. (HOWL)
Automate Your Wheel Strategy on HOWL
With Tiblio's Option Bot, you can configure your own wheel strategy including HOWL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOWL
- Rev/Share -0.0011
- Book/Share 0.6465
- PB 1.7478
- Debt/Equity 0.3257
- CurrentRatio 3.8728
- ROIC -0.8796
- MktCap 54840051.0
- FreeCF/Share -1.3895
- PFCF -0.8617
- PE -0.7106
- Debt/Assets 0.1211
- DivYield 0
- ROE -1.444
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today shared preclinical data at the 2025 Society for Immunotherapy of Cancer's …
Read More
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Details for the poster presentations are as follows:
Read More
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year –
Read More
About Werewolf Therapeutics, Inc. (HOWL)
- IPO Date 2021-04-30
- Website https://werewolftx.com
- Industry Biotechnology
- CEO Daniel J. Hicklin
- Employees 46